Trastuzumab Emtansine for the Treatment of HER-2 Positive Carcinoma Ex-pleomorphic Adenoma Metastatic to the Brain: A Case Report

Hassanieh, Ihab; Hilal, Lara; Feghali, Karine A. Al; Khalifeh, Ibrahim; Youssef, Bassem

doi:10.3389/fonc.2018.00274

Cited by 4 publications

(2 citation statements)

References 8 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An excellent response to T-DM1 was noted in a patient with carcinoma ex-pleomorphic adenoma. The patient showed resolution of the liver metastasis and significant intracranial disease response 12…”

Section: Discussionmentioning

confidence: 91%

Role of ado-trastuzumab emtansine (T-DM1) in HER2 positive salivary gland tumour with brain metastasis

Dhamne¹,

Koyyala²,

Chougule

et al. 2022

BMJ Case Rep

View full text Add to dashboard Cite

Malignant neoplasms of salivary gland neoplasms are rare and often involve the parotid gland. The primary treatment of these malignancies is surgery with or without adjuvant therapy. Chemotherapy or systemic therapy is indicated in recurrent or metastatic disease where surgery or radiotherapy is not possible. Salivary gland carcinomas, which are human epidermal growth factor receptor 2 (HER2) positive, show an aggressive behaviour with a poor prognosis. Targeting the HER2 pathway with drugs designed to block this pathway is an interesting novel therapy to treat salivary gland carcinomas. We report a case of a patient with HER 2-overexpressing parotid gland adenocarcinoma with brain metastasis, who was managed with ado-trastuzumab emtansine (T-DM1): a monoclonal antibody-cytotoxic drug conjugate that combines trastuzumab with the microtubule inhibitor, emtansine. The patient showed excellent response to the therapy. This case highlights the role of systemic chemotherapy with T-DM1 in HER2 positive salivary gland tumours that could be considered a part of the treatment regimen.

show abstract

Section: Discussionmentioning

confidence: 91%

Role of ado-trastuzumab emtansine (T-DM1) in HER2 positive salivary gland tumour with brain metastasis

Dhamne¹,

Koyyala²,

Chougule

et al. 2022

BMJ Case Rep

View full text Add to dashboard Cite

show abstract

“…In a phase II trial of Tmab monotherapy in fourteen patients with advanced HER2-positive salivary gland carcinomas, only one partial response (7.1%) was achieved [9]. However, a handful of case series have demonstrated dramatic responses to Tmab-based combination chemotherapy regimens against HER2-positive SDC, including CXPA, suggesting the potential utility of Tmab combination therapy (Table 1) [4, 5, 10, 11].…”

Section: Discussionmentioning

confidence: 99%

Trastuzumab-Based Combination Chemotherapy in Patients with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Carcinoma ex Pleomorphic Adenoma

et al. 2018

View full text Add to dashboard Cite

Background: Carcinoma ex pleomorphic adenoma (CXPA) is a rare histologic subtype of lacrimal gland and submandibular gland cancer. Currently, there is no standard treatment for metastatic CXPA, although some case reports have explored the role of targeted agents in chemotherapy. A few histopathologic analyses have shown that some of these tumors overexpress human epidermal growth factor receptor-2 (HER2), suggesting a potential role for HER2-based therapy. We report here two cases of metastatic CXPA that were treated with trastuzumab-based chemotherapy (IRB approved) with rapid and significant responses. Case Report 1: A 66-year-old male was diagnosed as HER2-positive CXPA of the right lacrimal gland with multiple bone and lymph node metastases. Combination chemotherapy with trastuzumab (Tmab) and nanoparticle albumin-bound paclitaxel (nabPTX) was initiated. A rapid response was confirmed, and after seven cycles of treatment, CR(complete response) was achieved. Case Report 2: A 67-year-old female was diagnosed with HER2 positive CXPA of the right submandibular gland. Multiple pulmonary metastatic lesions were detected after surgery, and combination chemotherapy with Tmab and nab-PTX was initiated. A rapid partial response (PR) was confirmed, and she eventually became disease-free. Conclusion: In the absence of definitive clinical trials, which are unlikely to be performed due to the rarity of HER2-positive CXPA, therapeutic information must be obtained from case reports. Some reports, such as this one, have suggested a potential utility of trastuzumab-based chemotherapy.

show abstract

Advances and challenges in precision medicine in salivary gland cancer

Lassche¹,

Boxtel²,

Ligtenberg

et al. 2019

Cancer Treatment Reviews

View full text Add to dashboard Cite

Trastuzumab Emtansine for the Treatment of HER-2 Positive Carcinoma Ex-pleomorphic Adenoma Metastatic to the Brain: A Case Report

Cited by 4 publications

References 8 publications

Role of ado-trastuzumab emtansine (T-DM1) in HER2 positive salivary gland tumour with brain metastasis

Role of ado-trastuzumab emtansine (T-DM1) in HER2 positive salivary gland tumour with brain metastasis

Trastuzumab-Based Combination Chemotherapy in Patients with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Carcinoma ex Pleomorphic Adenoma

Advances and challenges in precision medicine in salivary gland cancer

Contact Info

Product

Resources

About